Tag: "Infectious Disease Research Center"
More from this site
CSU Women in Science Symposium scheduled for International Women’s Day, March 8
Colorado State University’s Women in Science Network will be hosting its seventh annual symposium and celebrating its 10-year anniversary as an organization on International Women’s Day, March 8, at Canvas Stadium.
A Q&A on why CSU labs are safe
Rebecca Moritz is CSU’s biosafety director and director of the Office of Research Collaboration and Compliance. She’s responsible for lab safety at the university and leads the organization that sets professional standards for lab safety worldwide.
New insights into immune response with coronavirus vaccine candidate SolaVAX
The vaccine candidate helped minimize changes in tissues in the lungs caused by SARS-CoV-2.
CSU vaccine research advances, groundwork begins to develop coronavirus vaccine for the next pandemic
Researchers aim to create a vaccine candidate that would protect people from a spectrum of coronaviruses.
CSU alum leads state efforts for convalescent plasma consortium
Dr. John Eisenach was inspired by a mentor to create the Colorado COVID-19 Convalescent Plasma Project Consortium.
Research expenditures top $400 million, in historic first for CSU
Colorado State University’s spending on research activities reached a record $407 million for fiscal year 2020, a 2% increase over last year.
CSU researchers pivot, pursue, pioneer COVID-19 projects
Since the start of the coronavirus pandemic, Colorado State University has received more than $16 million in funding for COVID-19 research projects.
CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
An intertwined approach: CSU infectious disease experts make progress in national pandemic response
Sen. Cory Gardner was on campus to learn about CSU's work in testing, senior care facility surveillance and vaccine development.
CSU secures award from U.S. government for development of SolaVAX™ vaccine manufacturing process for SARS-CoV-2
A team of CSU researchers has entered into an agreement with the Biomedical Advanced Research and Development Authority to further develop a novel process that has the potential to inactivate the SARS-CoV-2 virus.